Alzamend Neuro gets Nasdaq extension to meet $2.5M equity rule by Sept 23, 2024

Alzamend Neuro, Inc.

Nasdaq Hearings Panel granted continued listing on Capital Market, subject to compliance with Listing Rule 5550(b)(1).
Company must demonstrate stockholder equity of at least $2.5 million on or before September 23, 2024.
Appeal hearing held May 9, 2024; panel decision received May 21, 2024.
CEO Stephan Jackman stated company is implementing its compliance plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.